A Look At Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance [Yahoo! Finance]
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth [Seeking Alpha]
What Halozyme Therapeutics (HALO)'s Upgraded Revenue Outlook and ENHANZE Acquisitions Strategy Means For Shareholders [Yahoo! Finance]
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.